Search Results for "R"

Recent draft pieces of legislation and regulation take aim at the rising cost of drugs, targeting drugs that claim the largest share of the health care budget and that face limited competition from generics or biosimilars.

Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.

Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

The Drug Pricing Lab submits a response to CMS-1678-P proposed changes to the Hospital Outpatient Prospective Payment Policy (OPPS).

To answer Health Affairs responses, Peter Bach and Nancy Yu point back to the research, emphasizing the original intent of the conservative R&D cost assumptions.

Drug prices in other high income countries for the 20 top selling drugs globally make up less than half of U.S. net drug prices.

At $500 per pill, buying Gilead could lower hepatitis C drug costs per patient to one-third their current level, making it affordable to rapidly treat the 2.7 million Americans that have HCV.

The high cost of R&D is used to explain why drugs giants merge, and why they must charge high prices. The reality is somewhat different.